All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.


The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Targeting ROR-1 with zilovertamab in MCL and CLL

Jan 30, 2023

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Hun Lee, MD Anderson Cancer Centre, Texas, US. We asked about the benefits of targeting ROR-1 with zilovertamab in patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).

Targeting ROR-1 with zilovertamab in MCL and CLL

Lee provides a summary of the latest safety and efficacy data from a phase I/II study of zilovertamab + ibrutinib in relapsed/refractory CLL and MCL, outlining the encouraging progression-free survival rates seen even in high-risk patients with TP53 alterations. Lee then discusses plans for further study of the apparent synergy between zilovertamab and ibrutinib and a phase III study of zilovertamab + ibrutinib versus ibrutinib + placebo in R/R MCL to validate these findings

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox